11，Burger EH,van der Meer JWM,Nijweide PJ.Osteoclast formation from mononuclear phagocytes.role of bone-forming cells.J Cell Biol,1984,99:1901-1906.
22，Takahashi N,Yamana M,Yoshiki S,et al.Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures.Endocrinology,1988,122:1373-1380.
33，Takahashi N,Udagawa N,Akatsu T,et al.Deficiency of osteoclasts in osteopetrotic mice is due to a defect in the local microenvironment provided by osteoblastic cells.Endocrinology,1991,128:1792-1796.
44，Takahashi N,Udagawa N,Akatsu T,et al.Role of colony-stimulating factors in osteoclast development.J Bone Miner Res,1991,6:977-985.
55，Fenton AJ,Martin TJ,Nicholson GC.Long-term culture of disaggregated rat osteoclasts:Inhibition of bone resorption and reduction of osteoclast-like cell number by calcitonin and PTHrp(107-199).J Cell Physiol,1993,155:1-7.
66，Jimi E,Nakamura I,Amano H,et al.Osteoclast function is activated by osteoblastic cell through a mechanism involving cell-to-cell contact.Endocrinology,1996,137:2187-2190.
77，Takahashi N,Udagawa N,Suda T. A new member of tumor necrosis factor ligand family,ODF/OPGL/TRANCE/RANKL,regulates osteoclast differentiation and function.Biochem Biophys Res Commun,1999,256(3):449-455.
88，Yamamoto M,Murakami T,Nishikawa M,et al.Hypocalcemic effect of osteoclastogenesis inhibitory factor/osteoprotegerin in the thyroparathyroidectomized rat.Endocrinology,1998,139(9):4012-4015.
99，Greenfield EM,Bi Y,Miyauchi A.Regulation of osteoclast activity.Life Sci,1999,65(11):1087-1102.
1010，Horwood NJ,Elliott J,Martin TJ,et al.Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells.Endocrinology,1998,139(11):4743-4746.
3Hansdottir H, Franzson L, Prest wood K, et al. The effect of raloxifene on markers of bone turnover in olderw omen living in long term care facillities [J]. J Am Geriatr Soc, 2004, 52(5).
4Delmas PD. Eastell R. GRANERO P, et al. The use of bio- chemical markers od bone turnover in osteoporosis [ J ]. Osteoporos Int,2000, Suppl 6 :S2 - S17.
5Ikegami A, Inoue S, Hosoi T, et al. Cell cycle dependent ex- pression and function of estrogen receptor in human osteoblastic cell [ J ]. Endocrinology, 1994,135:782 - 789.
6Papanicolaou DA, Wilder RL, Manolagecs SC, et al. The pathophophysiologic roles of interleukin -6 in human disease [ J ]. An of Inter Medic,1998,128(2) :127 - 137.
7Kalu DK, et al. The ovariectomized rat model of postmenopa- usal bone loss[J]. Bone Miner,1991,15(3) :175 - 191.
8Robinson Rechavi M, Escriva G H, Laudet V. The nuclear receptors uperfamily [ J ]. J Cell Sci, 2003,116 (4) : 585 - 586.
9Sabine O ,Pierre C ,Emilie C ,et al. Raloxifene--induced mye- loma cell apoptosis : A study of nuclear factor--KB inhibition and gene expression signature [ J ]. Molecular Pharmacology, 2006,69 : 1615.
10N akamura T, L iu J L, M orii H, et al. Effect of raloxifene on clinical fractures in Asian women with postmenopausal osteoporosis [ J]. J B one n inern etab, 2006, 24 (5).
